News

Clinical Trials Arena on MSN2d
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
Itovebi won US Food and Drug Administration (FDA) approval in this breast cancer indication based on INAVO120’s data late ...
Medical Dialogues16h
Roche Itovebi recommended by CHMP for EU approval for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
Basel: Roche has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...
pharmaphorum2d
ASCO 25: Roche places Itovebi marker in breast cancer
Roche's Itovebi was the first PI3K inhibitor to get approved as a first-line treatment for breast cancer last year – and new ...
Fierce Pharma3d
ASCO: Roche details Itovebi's survival benefit in certain breast cancers, further backing blockbuster plan
Roche, hoping to carve out a standard-of-care spot for its PI3K inhibitor Itovebi, now has another leg to stand on with new ...
Seeking Alpha2d
Roche wins EU endorsement for metastatic breast cancer treatment
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said that an advisory panel of the European Medicines Agency (EMA), endorsed its Itovebi drug combination for metastatic breast cancer. Issuing a positive opinion ...
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and ...
Finanznachrichten2d
F. Hoffmann-La Roche Ltd: CHMP recommends EU approval of Roche's Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer
The Itovebi-based regimen is approved for the treatment ... For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution ...